Prevenar 13 suspension for injection

País: Armènia

Idioma: anglès

Font: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

ingredients actius:

pneumococcal polysaccharide conjugate vaccine (pneumococcal polysaccharide serotype 1, pneumococcal polysaccharide serotype 3, pneumococcal polysaccharide serotype 4, pneumococcal polysaccharide serotype 5, pneumococcal polysaccharide serotype 6A, pneumococcal polysaccharide serotype 6B, pneumococcal polysaccharide serotype 7F, pneumococcal polysaccharide serotype 9V, pneumococcal polysaccharide serotype 14, pneumococcal polysaccharide serotype 18C, pneumococcal polysaccharide serotype 19A, pneumococcal pol

Disponible des:

Wyeth Pharmaceuticals

Codi ATC:

J07AL02

Designació comuna internacional (DCI):

pneumococcal polysaccharide conjugate vaccine (pneumococcal polysaccharide serotype 1, pneumococcal polysaccharide serotype 3, pneumococcal polysaccharide serotype 4, pneumococcal polysaccharide serotype 5, pneumococcal polysaccharide serotype 6A, pneumococcal polysaccharide serotype 6B, pneumococcal polysaccharide serotype 7F, pneumococcal polysaccharide serotype 9V, pneumococcal polysaccharide serotype 14, pneumococcal polysaccharide serotype 18C, pneumococcal polysaccharide serotype 19A, pneumococcal pol

Dosis:

2.2mcg/1 dose+ 2.2mcg/1 dose+ 2.2mcg/1 dose+ 2.2mcg/1 dose+ 2.2mcg/1 dose+ 4.4mcg/1 dose+ 2.2mcg/1 dose+ 2.2mcg/1 dose+ 2.2mcg/1

formulario farmacéutico:

suspension for injection

Unidades en paquete:

(1) pre-filled syringe 0.5ml/1 dose and needle, (10) pre-filled syringe 0.5ml/1dose

tipo de receta:

Prescription

Estat d'Autorització:

Registered

Data d'autorització:

2016-04-02

Informació per a l'usuari

Prevenar 13 suspension for injection
Pneumococcal polysaccharide conjugate vaccine (13 valent, adsorbed)
Prevenar 13 suspension for injection
Pneumococcal polysaccharide conjugate vaccine (13 valent, adsorbed)
Package Leaflet: Information
for the user
Prevenar 13 suspension for injection
Pneumococcal polysaccharide conjugate vaccine
(13 valent, adsorbed)
Read all of this leaflet carefully before you or your child receives
this vaccine because it contains important information for you.
–
Keep this leaflet. You may need to read it again.
–
If you have any further questions, ask your doctor, pharmacist or
nurse.
–
This vaccine has been prescribed for you or your child only. Do not
pass it on to others.
–
If you or your child get any side effects, talk to your doctor,
pharmacist or nurse. This includes any possible side effects not
listed in this leaflet. See section 4.
What is in this leaflet:
1. What Prevenar 13 is and what it is used for
2. What you need to know before you or your child receives Prevenar 13
3. How Prevenar 13 is given
4. Possible side effects
5. How to store Prevenar 13
6. Contents of the pack and other information
1. What Prevenar 13 is and what it is used for
Prevenar 13 is a pneumococcal vaccine given to:
•
children from 6 weeks to 17 years to help protect against diseases
such as: meningitis (inflammation around the brain), sepsis or
bacteraemia (bacteria in the blood stream), pneumonia
(lung infection) and ear infections
•
adults aged 18 years and older to help prevent disease such as:
pneumonia (lung infection), sepsis or bacteraemia (bacteria in the
blood stream) and meningitis (inflammation around the brain),
caused by 13 types of the bacteria _Streptococcus pneumoniae._
Prevenar 13, provides protection against 13 types of Streptococcus
pneumoniae bacteria, and replaces Prevenar, which provided protection
against 7 types.
The vaccine works by helping the body to make its own antibodies,
which protect you or your child against these diseases.
2. What you need to know before you

Fitxa tècnica

Ref: PN 18_0
Page 1 of 26
2016-0016967
1.
NAME OF THE MEDICINAL PRODUCT
Prevenar 13 suspension for injection
Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
1 dose (0.5 ml) contains:
Pneumococcal polysaccharide serotype 1
1
2.2 µg
Pneumococcal polysaccharide serotype 3
1
2.2 µg
Pneumococcal polysaccharide serotype 4
1
2.2 µg
Pneumococcal polysaccharide serotype 5
1
2.2 µg
Pneumococcal polysaccharide serotype 6A
1
2.2 µg
Pneumococcal polysaccharide serotype 6B
1
4.4 µg
Pneumococcal polysaccharide serotype 7F
1
2.2 µg
Pneumococcal polysaccharide serotype 9V
1
2.2 µg
Pneumococcal polysaccharide serotype 14
1
2.2 µg
Pneumococcal polysaccharide serotype 18C
1
2.2 µg
Pneumococcal polysaccharide serotype 19A
1
2.2 µg
Pneumococcal polysaccharide serotype 19F
1
2.2 µg
Pneumococcal polysaccharide serotype 23F
1
2.2 µg
1
Conjugated to CRM
197
carrier protein and adsorbed on aluminium phosphate (0.125 mg
aluminium).
Excipients with known effect
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Suspension for injection.
The vaccine is a homogeneous white suspension.
_ _
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Active immunisation for the prevention of invasive disease, pneumonia
and acute otitis media caused
by _Streptococcus pneumoniae_ in infants, children and adolescents
from 6 weeks to 17 years of age.
Active immunisation for the prevention of invasive disease and
pneumonia caused by_ Streptococcus _
_pneumoniae _in adults ≥18 years of age and the elderly.
See sections 4.4 and 5.1 for information on protection against
specific pneumococcal serotypes.
The use of Prevenar 13 should be determined on the basis of official
recommendations taking into
consideration the risk of invasive disease and pneumonia in different
age groups, underlying
comorbidities as well as the variability of serotype epidemiology in
different geographical areas.
Ref: PN 18_0
Page 2 of 26
2016-0016967
4.2
POSOLOGY AND METHOD OF ADMINISTRATI